メインコンテンツにスキップ

Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling and Simulation

Biologic drug development is a rapidly evolving sector in the biopharmaceutical industry. Immunogenicity is an inherent challenge with this complex class of drugs. A quantitative systems pharmacology approach can be used to predict and better manage immunogenicity, and as a tool to guide clinical and regulatory decision-making in biologics drug development.

How Model-based Approaches Can Improve Precision Dosing in Clinical Care

In this webinar, Dr. Adam Darwich, Certara Lecturer in Precision Dosing at the Manchester Pharmacy School at The University of Manchester, presented several case studies that illustrate how PBPK models have been used to predict drug-drug interactions, extrapolate to special populations, and optimize clinical study design.

Using Model-based Meta-analysis to Improve Decision-making in Drug Development

Making the right choices in drug development often means the difference between getting a new medication to patients and it ending up in the scrap heap of failed programs. 承認された医薬品および開発中の医薬品の両方に関する公開情報は非常に多く存在します。こうした状況下で、スポンサー企業はどのように臨床試験データに基づいて、開発医薬品の成功への道筋をつける知見を獲得することができるでしょうか?

Safe Dosing for Organ Impairment

A small pharma company leveraged Certara’s consulting services to predict the effects of organ impairment on exposure for a new drug formulation.

1 of 3
Powered by Translations.com GlobalLink OneLink Software